Clinical Trial: A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793709) titled 'A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy' on Jan. 21.

Brief Summary: The primary purpose of this study is to investigate the safety of Tasfygo.

Study Start Date: Feb. 01

Study Type: OBSERVATIONAL

Condition: Biliary Tract Cancer

Intervention: OTHER: No Intervention

This is a non-interventional study.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eisai Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....